Posts

Madrigal Pharmaceuticals Secures $4.4B Deal for Six Preclinical siRNA Programs Targeting MASH from Ribo Life Science

Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH